Compare METC & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | METC | TNGX |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | N/A | 2020 |
| Metric | METC | TNGX |
|---|---|---|
| Price | $14.16 | $17.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $33.94 | $17.00 |
| AVG Volume (30 Days) | 1.9M | ★ 3.1M |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $62,384,000.00 |
| Revenue This Year | $22.05 | N/A |
| Revenue Next Year | $13.17 | $13.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $6.30 | $1.04 |
| 52 Week High | $57.80 | $16.89 |
| Indicator | METC | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 36.31 | 75.71 |
| Support Level | $8.95 | $6.95 |
| Resistance Level | $19.00 | N/A |
| Average True Range (ATR) | 1.35 | 1.14 |
| MACD | -0.12 | 0.38 |
| Stochastic Oscillator | 7.54 | 89.68 |
Ramaco Resources Inc is a United States-based company that operates as a pure-play metallurgical coal company with operations in southern West Virginia and southwestern Virginia. Its portfolio includes high-quality metallurgical coal reserves & resources, with a focus on properties such as Elk Creek, Berwind, Knox Creek, and Maben. These properties are strategically located to serve North American blast furnace steel mills and coke plants, as well as international metallurgical coal consumers. Additionally, the company controls mineral deposits in Sheridan, Wyoming, exploring potential opportunities in rare earth elements and coal-to-carbon-based products. Operations are concentrated in the Appalachian basin, with active mines at Elk Creek, Berwind, Knox Creek, and Maben mining complexes.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.